Description

Overview: Tesamorelin 10 mg is a high-purity synthetic growth hormone–releasing hormone (GHRH) analog supplied in lyophilized (freeze-dried) powder form for laboratory research applications. It is a 44–amino acid modified peptide derived from endogenous GHRH, designed with structural modifications that increase stability and resistance to enzymatic degradation. In controlled research environments, Tesamorelin is widely studied for its interaction with pituitary GHRH receptors, leading to activation of growth hormone (GH) secretion and downstream IGF-1 signaling pathways. Scientific literature describes its use in experimental models evaluating growth hormone axis regulation, lipid metabolism pathways, and body composition research, particularly related to visceral fat reduction mechanisms. Clinical references also note its approved pharmaceutical use (Egrifta SV) for HIV-associated lipodystrophy, where it is administered under medical supervision via subcutaneous injection. Each vial is manufactured under strict quality standards and labeled for Research Use Only (RUO). This product is strictly not intended to diagnose, treat, cure, or prevent any disease and is not approved for human or veterinary use. It is intended exclusively for qualified laboratory research purposes.